These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 36359323)
61. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin. Ak G; Tada Y; Shimada H; Metintas S; Ito M; Hiroshima K; Tagawa M; Metintas M BMC Cancer; 2017 Mar; 17(1):212. PubMed ID: 28335760 [TBL] [Abstract][Full Text] [Related]
62. Detection of carbonic anhydrase IX protein in the diagnosis of malignant pleural effusion by enzyme-linked immunosorbent assay and immunocytochemistry. Liao ND; Lee WY Cancer Cytopathol; 2012 Aug; 120(4):269-75. PubMed ID: 22367930 [TBL] [Abstract][Full Text] [Related]
63. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232 [TBL] [Abstract][Full Text] [Related]
64. Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Porcel JM; Hernández P; Martínez-Alonso M; Bielsa S; Salud A Chest; 2015 Feb; 147(2):502-512. PubMed ID: 25188411 [TBL] [Abstract][Full Text] [Related]
65. The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion. Fiorelli A; Morgillo F; Fasano M; Vicidomini G; Di Crescenzo VG; Di Domenico M; Accardo M; Santini M Interact Cardiovasc Thorac Surg; 2013 Mar; 16(3):263-9. PubMed ID: 23190621 [TBL] [Abstract][Full Text] [Related]
66. Carcinoembryonic antigen in pleural effusions. Diagnostic value in malignant mesothelioma. Faravelli B; D'Amore E; Nosenzo M; Betta PG; Donna A Cancer; 1984 Mar; 53(5):1194-7. PubMed ID: 6362839 [TBL] [Abstract][Full Text] [Related]
67. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in diagnosis of pleural effusion of malignant origin. Fiorelli A; Ricci S; Feola A; Mazzella A; D'Angelo L; Santini M; Di Domenico M; Di Carlo A Interact Cardiovasc Thorac Surg; 2016 Apr; 22(4):411-8. PubMed ID: 26769731 [TBL] [Abstract][Full Text] [Related]
68. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181 [TBL] [Abstract][Full Text] [Related]
69. The diagnostic yield of pleural fluid cytology in malignant pleural effusions. Ong KC; Indumathi V; Poh WT; Ong YY Singapore Med J; 2000 Jan; 41(1):19-23. PubMed ID: 10783675 [TBL] [Abstract][Full Text] [Related]
70. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma. Atagi S; Ogawara M; Kawahara M; Sakatani M; Furuse K; Ueda E; Yamamoto S Jpn J Clin Oncol; 1997 Oct; 27(5):293-7. PubMed ID: 9390204 [TBL] [Abstract][Full Text] [Related]
71. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. DeLong P; Carroll RG; Henry AC; Tanaka T; Ahmad S; Leibowitz MS; Sterman DH; June CH; Albelda SM; Vonderheide RH Cancer Biol Ther; 2005 Mar; 4(3):342-6. PubMed ID: 15846066 [TBL] [Abstract][Full Text] [Related]
72. Different expression of FoxM1 in human benign and malignant pleural effusion. Tang Z; Li H; Zhu H; Bai C Med Oncol; 2015 Jan; 32(1):312. PubMed ID: 25491139 [TBL] [Abstract][Full Text] [Related]
73. Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions. Arnold DT; Hamilton FW; Elvers KT; Frankland SW; Zahan-Evans N; Patole S; Medford A; Bhatnagar R; Maskell NA Am J Respir Crit Care Med; 2020 Jun; 201(12):1545-1553. PubMed ID: 32069085 [No Abstract] [Full Text] [Related]
74. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Davies HE; Sadler RS; Bielsa S; Maskell NA; Rahman NM; Davies RJ; Ferry BL; Lee YC Am J Respir Crit Care Med; 2009 Sep; 180(5):437-44. PubMed ID: 19299498 [TBL] [Abstract][Full Text] [Related]
75. Diagnostic value of tumour markers in pleural effusions. Volarić D; Flego V; Žauhar G; Bulat-Kardum L Biochem Med (Zagreb); 2018 Feb; 28(1):010706. PubMed ID: 29472801 [TBL] [Abstract][Full Text] [Related]
76. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology. Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174 [TBL] [Abstract][Full Text] [Related]
77. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206 [TBL] [Abstract][Full Text] [Related]
78. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study. Capkova L; Koubkova L; Kodet R Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939 [TBL] [Abstract][Full Text] [Related]
79. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166 [TBL] [Abstract][Full Text] [Related]
80. The Prevalence and Clinical Relevance of Nonexpandable Lung in Malignant Pleural Mesothelioma. A Prospective, Single-Center Cohort Study of 229 Patients. Bibby AC; Halford P; De Fonseka D; Morley AJ; Smith S; Maskell NA Ann Am Thorac Soc; 2019 Oct; 16(10):1273-1279. PubMed ID: 31189069 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]